

Dr Esmaili completed medicine in Tehran University of Medical Science and PhD in Medicine at the University of Sydney. He is a group leader on Fatty Liver and Cancer at the Storr Liver Center, The Westmead Institute for Medical Research. His work focuses on the mechanism of inflammation triggered by high dietary cholesterol and new therapeutic approaches for advanced form of non-alcoholic fatty liver disease. He believes that taking a system biology approach in NAFLD/NASH will pave the way to unravel the complexity of NASH as a metabolic syndrome. He is using a high throughput mass cytometry approach to immunophenotype the systemic and liver inflammatory response to hepatic cholesterol accumulation.